Compare ANNX & SHEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | SHEN |
|---|---|---|
| Founded | 2011 | 1902 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 730.4M | 803.5M |
| IPO Year | 2020 | 1994 |
| Metric | ANNX | SHEN |
|---|---|---|
| Price | $5.47 | $14.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $16.50 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 2.2M | 226.9K |
| Earning Date | 03-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.76% |
| EPS Growth | ★ 42.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $357,854,000.00 |
| Revenue This Year | N/A | $6.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 9.08 |
| 52 Week Low | $1.29 | $9.67 |
| 52 Week High | $7.18 | $15.92 |
| Indicator | ANNX | SHEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 55.64 |
| Support Level | $4.77 | $13.97 |
| Resistance Level | $5.61 | $15.86 |
| Average True Range (ATR) | 0.35 | 0.64 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 33.89 | 38.83 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Shenandoah Telecommunications Co with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.